Klinefelter Syndrome
A genetic condition in males born with an extra X chromosome, causing infertility, small testes, enlarged breasts, and low testosterone.
Emergency Management: None inherently caused directly by the syndrome itself.
Klinefelter Syndrome is a common chromosomal disorder affecting males, defined by the presence of one or more extra X chromosomes (most classically 47,XXY). It is the most common genetic cause of male hypogonadism and infertility.
Detailed Overview
The extra X chromosome interferes with male sexual development, specifically causing dysgenesis of the seminiferous tubules and Leydig cell dysfunction. The condition usually goes undiagnosed until puberty or adulthood when patients present with delayed puberty, gynecomastia, or infertility (azoospermia). Individuals typically have a tall stature with long limbs. The hypogonadism (low testosterone) leads to reduced muscle mass, decreased body hair, and increased risk of osteoporosis. Cognitive and language delays may also be present, though intelligence is usually in the normal range.
Epidemiology & Demographics
Occurs in approximately 1 in 500 to 1,000 live male births. It is highly underdiagnosed, with only about 25% of cases diagnosed in the patient's lifetime.
Etiological Mechanism
Results from a non-disjunction event of the sex chromosomes during maternal or paternal meiosis (spermatogenesis or oogenesis).
Primary Causes
["Meiotic nondisjunction (47,XXY karyotype in ~80% of cases)", "Mosaicism (46,XY/47,XXY in ~20% of cases, often with milder symptoms)"]
The extra X chromosome(s) undergo X-inactivation, but some genes escape inactivation, leading to overexpression. This causes progressive hyalinization and fibrosis of the seminiferous tubules (leading to absent spermatogenesis and decreased Inhibin B) and impaired Leydig cell function (leading to decreased testosterone). The lack of negative feedback from Inhibin B and testosterone causes hypersecretion of FSH and LH from the pituitary gland, resulting in hypergonadotropic hypogonadism. The altered testosterone-to-estrogen ratio drives feminizing features like gynecomastia.
Diagnostic Criteria & Guidelines
Clinical suspicion based on physical exam (microorchidism, tall stature) and endocrine profile (hypergonadotropic hypogonadism), confirmed definitively by Karyotype analysis (chromosome microarray or G-banding) showing 47,XXY.
Testosterone Replacement Therapy (TRT): Initiated at puberty (around age 12-14) or upon diagnosis to promote virilization, increase muscle mass, improve mood, and preserve bone density. Examples: Intramuscular Testosterone Cypionate (e.g., 50-200 mg every 1-2 weeks) or topical testosterone gels (e.g., 1.62% gel applied daily).
Second-Line & Adjunctive Therapy
For fertility: Microdissection Testicular Sperm Extraction (micro-TESE) to retrieve viable sperm directly from the testes, followed by Intracytoplasmic Sperm Injection (ICSI) for in vitro fertilization.
Surgical & Procedural Management
Mastectomy (breast reduction surgery) for cosmetic management of severe gynecomastia and to reduce breast cancer risk.
Patient Counseling & Advice
Discuss infertility early. Reassure the patient that while natural conception is rare, biological fatherhood is possible for up to 50% of men via micro-TESE and IVF/ICSI. Address the psychological impact of delayed puberty or gynecomastia.
Follow-Up & Monitoring Schedule
Annual monitoring of TRT (check serum testosterone, hematocrit for polycythemia, PSA). Annual breast exams due to breast cancer risk. Routine screening for diabetes and metabolic syndrome.
Preventive Strategies
Not preventable. Prenatal diagnosis via chorionic villus sampling (CVS) or amniocentesis is possible.
Normal lifespan. Morbidity is driven by complications of hypogonadism (osteoporosis, cardiovascular risk) and slightly increased risks of certain malignancies (breast cancer, extragonadal germ cell tumors), but quality of life is generally good with early TRT.